AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1
Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 28-28
10.1002/hon.2437_7